Nerandomilast-Associated Pneumonitis With a Positive Rechallenge: A Case Report.
- 1Department of Respiratory Medicine Fukuoka University Hospital Fukuoka Japan.
Abstract
Nerandomilast is an oral preferential phosphodiesterase 4B inhibitor that slows the decline in forced vital capacity in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Nerandomilast-associated pneumonitis has not previously been reported. A 33-year-old woman with advanced unclassifiable idiopathic interstitial pneumonia developed fever, dyspnoea, hypoxaemia and new bilateral consolidations and ground-glass opacities 9 days after starting nerandomilast. The drug was withdrawn, and her clinical, inflammatory and radiological findings improved during antimicrobial and corticosteroid treatment. Nerandomilast was subsequently restarted at a reduced dose. The following day, symptoms, inflammatory markers and pulmonary opacities worsened and improved again after drug withdrawal. Bronchoalveolar lavage and lung biopsy were not performed because severe chronic hypercapnia made invasive procedures unsafe. The temporal association and positive rechallenge strongly supported nerandomilast-associated pneumonitis. Clinicians should consider drug-induced pneumonitis when new pulmonary infiltrates develop after starting an antifibrotic agent.
Related
- Recurrent Pancytopenia Associated with Olanzapine Rechallenge: A Rare Case Report with Literature Review
- Case Report: Hyperactive delirium with psychotic symptoms associated with severe hypothyroidism during pembrolizumab therapy. Complete remission after levothyroxine and no recurrence after pembrolizumab rechallenge
- Contemporary Management and Rechallenge Practices for 5‐Fluorouracil–Associated Cardiotoxicity: Insights From an International Cardio‐Oncology Society Survey
- Pneumocystis Jirovecii Pneumonia Associated with Prolonged CD4-positive T-cell Depletion after Bendamustine-Rituximab Therapy: A Case Report
- Eosinophilic Granulomatosis with Polyangiitis Presenting with an Acute Hypersensitivity Pneumonitis-like CT Pattern: A Case Report
BibTeX
@article{yanagihara2026nerandomilastassociated,
title = {{Nerandomilast-Associated Pneumonitis With a Positive Rechallenge: A Case Report.}},
author = {Toyoshi Yanagihara and Eriko Kinoshita and Yuuka Sakaki and Yuko Fujino and Masaki Fujita},
journal = {Respirology case reports},
year = {2026},
month = oct,
doi = {10.1002/rcr2.70786},
url = {https://europepmc.org/article/MED/42903208},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Nerandomilast-Associated Pneumonitis With a Positive Rechallenge: A Case Report.
AU - Toyoshi Yanagihara
AU - Eriko Kinoshita
AU - Yuuka Sakaki
AU - Yuko Fujino
AU - Masaki Fujita
PY - 2026
DA - 2026/10/19
JO - Respirology case reports
DO - 10.1002/rcr2.70786
UR - https://europepmc.org/article/MED/42903208
AB - Nerandomilast is an oral preferential phosphodiesterase 4B inhibitor that slows the decline in forced vital capacity in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Nerandomilast-associated pneumonitis has not previously been reported. A 33-year-old woman with advanced unclassifiable idiopathic interstitial pneumonia developed fever, dyspnoea, hypoxaemia and new bilateral consolidations and ground-glass opacities 9 days after starting nerandomilast. The drug was withdrawn, and her clinical, inflammatory and radiological findings improved during antimicrobial and corticosteroid treatment. Nerandomilast was subsequently restarted at a reduced dose. The following day, symptoms, inflammatory markers and pulmonary opacities worsened and improved again after drug withdrawal. Bronchoalveolar lavage and lung biopsy were not performed because severe chronic hypercapnia made invasive procedures unsafe. The temporal association and positive rechallenge strongly supported nerandomilast-associated pneumonitis. Clinicians should consider drug-induced pneumonitis when new pulmonary infiltrates develop after starting an antifibrotic agent.
SN - 2051-3380
ER -